Your Health, We Care
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
from FDA,2023.09
Lucius Version of Momelotinib: Dosage and Administration, Indications, PrecautionsIndicationsMomelot···【more】
Recommended：2082025-16-12
Mechanism of Action of MomelotinibMyelofibrosis (MF) is a rare blood cancer, and when it coexists with anemia, patients often face challenges beyond a single dimension. Anemia itse···【more】
Article source：Lucius LaosRelease date：2026-06-22Recommended：126
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis.【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：186
Lucius Version of Momelotinib: Dosage and Administration, Indications, PrecautionsIndicationsMomelotinib is indicated for the treatment of adult patients with anemia associated wit···【more】
Article source：Lucius LaosRelease date：2025-12-16Recommended：208
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
